The Experts below are selected from a list of 207 Experts worldwide ranked by ideXlab platform
Chengping Lu - One of the best experts on this subject based on the ideXlab platform.
-
A novel vaccine against Porcine circoVirus type 2 (PCV2) and Streptococcus equi ssp. zooepidemicus (SEZ) co-infection.
Veterinary microbiology, 2014Co-Authors: Zhe Ma, Xu-qiu Yang, Chengping LuAbstract:To develop a vaccine against Porcine circoVirus type 2 (PCV2) and Streptococcus equi ssp. zooepidemicus (SEZ) co-infection, the genes of porcine IL-18, capsid protein (Cap) of PCV2 and M-like protein (SzP) of SEZ were inserted into the Swinepox Virus (SPV) genome by homologous recombination. The recombinant Swinepox Virus rSPV-ICS was verified by PCR and indirect immunofluorescence assays. To evaluate the immunogenicity of rSPV-ICS, 28 PCV2 and SEZ seronegative Bama minipigs were immunized with rSPV-ICS (n=8), commercial PCV2 vaccine and SEZ vaccine (n=8) or wild type SPV (n=8). The results showed that SzP-specific antibody and PCV2 neutralizing antibody of the rSPV-ICS immunized group increased significantly compared to the wild type SPV treated group after vaccination and increased continuously over time. The levels of IL-4 and IFN-γ in the rSPV-ICS immunized group were significantly higher than the other three groups, respectively. After been co-challenged with PCV2 and SEZ, 87.5% piglets in rSPV-ICS immunized group were survived. Significant reductions in gross lung lesion score, histopathological lung lesion score, and lymph node lesion score were noticed in the rSPV-ICS immunized group compared with the wtSPV treated group. The results suggested that the recombinant rSPV-ICS provided piglets with significant protection against PCV2-SEZ co-infection; thus, it offers proof-of-principle for the development of a vaccine for the prevention of these swine diseases.
-
protection of guinea pigs by vaccination with a recombinant Swinepox Virus co expressing ha1 genes of swine h1n1 and h3n2 influenza Viruses
Archives of Virology, 2013Co-Authors: Jiarong Xu, Dongyan Huang, Deji Yang, Jiaping Xu, Chengping LuAbstract:Swine influenza (SI) is an acute respiratory infectious disease of swine caused by swine influenza Virus (SIV). SIV is not only an important respiratory pathogen in pigs but also a potent threat to human health. Here, we report the construction of a recombinant Swinepox Virus (rSPV/H3-2A-H1) co-expressing hemagglutinin (HA1) of SIV subtypes H1N1 and H3N2. Immune responses and protection efficacy of the rSPV/H3-2A-H1 were evaluated in guinea pigs. Inoculation of rSPV/H3-2A-H1 yielded neutralizing antibodies against SIV H1N1 and H3N2. The IFN-γ and IL-4 concentrations in the supernatant of lymphocytes stimulated with purified SIV HA1 antigen were significantly higher (P < 0.01) than those of the control groups. Complete protection of guinea pigs against SIV H1N1 or H3N2 challenge was observed. No SIV shedding was detected from guinea pigs vaccinated with rSPV/H3-2A-H1 after challenge. Most importantly, the guinea pigs immunized with rSPV/H3-2A-H1 did not show gross and micrographic lung lesions. However, the control guinea pigs experienced distinct gross and micrographic lung lesions at 7 days post-challenge. Our data suggest that the recombinant Swinepox Virus encoding HA1 of SIV H1N1 and H3N2 might serve as a promising candidate vaccine for protection against SIV H1N1 and H3N2 infections.
-
immune responses and protective efficacy of a recombinant Swinepox Virus co expressing ha1 genes of h3n2 and h1n1 swine influenza Virus in mice and pigs
Veterinary Microbiology, 2013Co-Authors: Jiarong Xu, Dongyan Huang, Jiaping Xu, Wen Chen, Chengping LuAbstract:The recombinant swine poxVirus rSPV/H3-2A-H1 co-expressing HA1 genes of H3N2 and H1N1 subtype SIV has been constructed and identified. Inoculations of rSPV/H3-2A-H1 yielded ELISA and neutralization antibodies against SIV H1N1 and H3N2, and elicited potent H1N1 and H3N2 SIV-specific INF-γ response from T-lymphocytes in mice and pigs in this study. Complete protection against SIV H1N1 or H3N2 challenge in pigs was observed.
-
construction and immunogenicity of recombinant Swinepox Virus expressing capsid protein of pcv2
Vaccine, 2012Co-Authors: Chengping LuAbstract:To explore development of a vaccine against PCV2 infections, the gene of capsid protein (Cap) was inserted into the Swinepox Virus (SPV) genome by homologous recombination. The recombinant Swinepox Virus expressing capsid protein (rSPV-cap) was verified by PCR, western blot and immunofluorescence assays. To evaluate the immunogenicity of rSPV-cap, twenty-four PCV2 seronegative minipigs were immunized with rSPV-cap, wild type SPV (wtSPV; negative control), or PBS (challenge control). After inoculation with PCV2, pigs in the rSPV-cap immunized group showed significantly higher average daily weight gain (ADG) and shorter fever duration compared with the wtSPV treated group (P < 0.05). Cap-specific antibody in the rSPV-cap immunized group increased dramatically after vaccination and increased continuously over time. PCV2 genomic copies in the serum of rSPV-cap immunized pigs were significantly less compared with the wtSPV treated group at all time points after inoculation (P < 0.01). Significant reduction in gross lung lesion scores, histopathological lung lesion scores, and lymph node lesion scores were noted in the rSPV-cap immunized group compared with the wtSPV treated group (P < 0.01). The results suggested that the recombinant rSPV-cap provided pigs with significant protection from PCV2-associated disease; thus, it offers proof-of-principle for the development of a vaccine for the prevention of PCV2-associated disease in pigs.
-
immune responses and protection efficacy of a recombinant Swinepox Virus expressing ha1 against swine h3n2 influenza Virus in mice and pigs
Virus Research, 2012Co-Authors: Jiarong Xu, Dongyan Huang, Chengping LuAbstract:Swine influenza Virus (SIV) is not only an important respiratory pathogen in pigs but also a potent threat to human health. Even though immunization with recombinant vaccinia poxViruses expressing protective antigens as a vaccination strategy has been widely used for many infectious diseases, development of recombinant Swinepox Virus (rSPV) vector for this purpose has been less successful. Here, we report the construction of a recombinant Swinepox Virus (rSPV) expressing hemagglutinin (HA1) of H3N2 SIV (rSPV-H3). Immune responses and protection efficacy of the vaccination vector were assessed in both mouse and pig models. Prime and boost inoculations of rSPV-H3 yielded neutralization antibody against SIV and elicited potent H3N2 SIV-specific INF-γ response from T-lymphocytes. Complete protection of pigs against H3N2 SIV challenge was achieved. No pigs showed severe systemic and local reactions and no SIV was found shed from the pigs vaccinated with rSPV-H3 after challenge. The data suggest that the SPV-based recombinant vector expressing HA1 of H3N2 SIV might serve as a promising SIV vaccine for protection against SIV infection.
Dongyan Huang - One of the best experts on this subject based on the ideXlab platform.
-
protection of guinea pigs by vaccination with a recombinant Swinepox Virus co expressing ha1 genes of swine h1n1 and h3n2 influenza Viruses
Archives of Virology, 2013Co-Authors: Jiarong Xu, Dongyan Huang, Deji Yang, Jiaping Xu, Chengping LuAbstract:Swine influenza (SI) is an acute respiratory infectious disease of swine caused by swine influenza Virus (SIV). SIV is not only an important respiratory pathogen in pigs but also a potent threat to human health. Here, we report the construction of a recombinant Swinepox Virus (rSPV/H3-2A-H1) co-expressing hemagglutinin (HA1) of SIV subtypes H1N1 and H3N2. Immune responses and protection efficacy of the rSPV/H3-2A-H1 were evaluated in guinea pigs. Inoculation of rSPV/H3-2A-H1 yielded neutralizing antibodies against SIV H1N1 and H3N2. The IFN-γ and IL-4 concentrations in the supernatant of lymphocytes stimulated with purified SIV HA1 antigen were significantly higher (P < 0.01) than those of the control groups. Complete protection of guinea pigs against SIV H1N1 or H3N2 challenge was observed. No SIV shedding was detected from guinea pigs vaccinated with rSPV/H3-2A-H1 after challenge. Most importantly, the guinea pigs immunized with rSPV/H3-2A-H1 did not show gross and micrographic lung lesions. However, the control guinea pigs experienced distinct gross and micrographic lung lesions at 7 days post-challenge. Our data suggest that the recombinant Swinepox Virus encoding HA1 of SIV H1N1 and H3N2 might serve as a promising candidate vaccine for protection against SIV H1N1 and H3N2 infections.
-
immune responses and protective efficacy of a recombinant Swinepox Virus co expressing ha1 genes of h3n2 and h1n1 swine influenza Virus in mice and pigs
Veterinary Microbiology, 2013Co-Authors: Jiarong Xu, Dongyan Huang, Jiaping Xu, Wen Chen, Chengping LuAbstract:The recombinant swine poxVirus rSPV/H3-2A-H1 co-expressing HA1 genes of H3N2 and H1N1 subtype SIV has been constructed and identified. Inoculations of rSPV/H3-2A-H1 yielded ELISA and neutralization antibodies against SIV H1N1 and H3N2, and elicited potent H1N1 and H3N2 SIV-specific INF-γ response from T-lymphocytes in mice and pigs in this study. Complete protection against SIV H1N1 or H3N2 challenge in pigs was observed.
-
immune responses and protection efficacy of a recombinant Swinepox Virus expressing ha1 against swine h3n2 influenza Virus in mice and pigs
Virus Research, 2012Co-Authors: Jiarong Xu, Dongyan Huang, Chengping LuAbstract:Swine influenza Virus (SIV) is not only an important respiratory pathogen in pigs but also a potent threat to human health. Even though immunization with recombinant vaccinia poxViruses expressing protective antigens as a vaccination strategy has been widely used for many infectious diseases, development of recombinant Swinepox Virus (rSPV) vector for this purpose has been less successful. Here, we report the construction of a recombinant Swinepox Virus (rSPV) expressing hemagglutinin (HA1) of H3N2 SIV (rSPV-H3). Immune responses and protection efficacy of the vaccination vector were assessed in both mouse and pig models. Prime and boost inoculations of rSPV-H3 yielded neutralization antibody against SIV and elicited potent H3N2 SIV-specific INF-γ response from T-lymphocytes. Complete protection of pigs against H3N2 SIV challenge was achieved. No pigs showed severe systemic and local reactions and no SIV was found shed from the pigs vaccinated with rSPV-H3 after challenge. The data suggest that the SPV-based recombinant vector expressing HA1 of H3N2 SIV might serve as a promising SIV vaccine for protection against SIV infection.
-
immune responses and protective efficacy of a recombinant Swinepox Virus expressing ha1 against swine h1n1 influenza Virus in mice and pigs
Vaccine, 2012Co-Authors: Jiarong Xu, Dongyan Huang, Chengping LuAbstract:Abstract Swine influenza Virus (SIV) is not only an important respiratory pathogen in pigs but also a potent threat to human health. Although immunization with recombinant poxViruses expressing protective antigens as vaccines has been widely used for against many infectious diseases, development of recombinant Swinepox Virus (rSPV) vector for the purpose has been less successful. Here, we report the construction of a recombinant Swinepox Virus (rSPV-HA1) expressing hemagglutinin (HA1) of H1N1 SIV. Immune responses and protection efficacy of the vaccination vector were evaluated in both the mouse model and the natural host: pig. Prime and boost inoculations of rSPV-HA1 yielded high levels of neutralization antibody against SIV and elicited potent H1N1 SIV-specific IFN-γ response from T-lymphocytes. Complete protection of pigs against H1N1 SIV challenge was observed. No pigs showed evident systemic and local reactions to the vaccine and no SIV shedding was detected from pigs vaccinated with rSPV-HA1 after challenge. Our data demonstrated that the recombinant Swinepox Virus encoding HA1 of SIV H1N1 may serve as a promising SIV vaccine for protection against SIV infection.
-
First insights into the protective effects of a recombinant Swinepox Virus expressing truncated MRP of Streptococcus suis type 2 in mice.
Berliner Und Munchener Tierarztliche Wochenschrift, 2012Co-Authors: Dongyan Huang, Jiarong Xu, Chengping LuAbstract:: To explore the potential of the Swinepox Virus (SPV) as vector for Streptococcus suis vaccines, a vector system was developed for the construction of a recombinant SPV carrying bacterial genes. Using this system, a recombinant Virus expressing truncated muramidase-released protein (MRP) of S. suis type 2 (SS2), designated rSPV-MRP, was produced and identified by PCR, western blotting and immunofluorescence assays. The rSPV-MRP was found to be only slightly attenuated in PK-15 cells, when compared with the wild-type Virus. After immunization intramuscularly with rSPV-MRP, SS2 inactive vaccine (positive control), wild-type SPV (negative control) and PBS (blank control) respectively, all CD1 mice were challenged with a lethal dose or a sublethal dose of SS2 highly virulent strain ZY05719. While SS2 inactive vaccine protected all mice, immunization with rSPV-MRP resulted in 60% survival and protected mice against a lethal dose of the highly virulent SS2 strain, compared with the negative control (P < 0.05). Our data indicate that animals immunized with rSPV-MRP had a significantly reduced bacterial burden in all organs examined, compared to negative controls and blank controls (P
Jiarong Xu - One of the best experts on this subject based on the ideXlab platform.
-
protection of guinea pigs by vaccination with a recombinant Swinepox Virus co expressing ha1 genes of swine h1n1 and h3n2 influenza Viruses
Archives of Virology, 2013Co-Authors: Jiarong Xu, Dongyan Huang, Deji Yang, Jiaping Xu, Chengping LuAbstract:Swine influenza (SI) is an acute respiratory infectious disease of swine caused by swine influenza Virus (SIV). SIV is not only an important respiratory pathogen in pigs but also a potent threat to human health. Here, we report the construction of a recombinant Swinepox Virus (rSPV/H3-2A-H1) co-expressing hemagglutinin (HA1) of SIV subtypes H1N1 and H3N2. Immune responses and protection efficacy of the rSPV/H3-2A-H1 were evaluated in guinea pigs. Inoculation of rSPV/H3-2A-H1 yielded neutralizing antibodies against SIV H1N1 and H3N2. The IFN-γ and IL-4 concentrations in the supernatant of lymphocytes stimulated with purified SIV HA1 antigen were significantly higher (P < 0.01) than those of the control groups. Complete protection of guinea pigs against SIV H1N1 or H3N2 challenge was observed. No SIV shedding was detected from guinea pigs vaccinated with rSPV/H3-2A-H1 after challenge. Most importantly, the guinea pigs immunized with rSPV/H3-2A-H1 did not show gross and micrographic lung lesions. However, the control guinea pigs experienced distinct gross and micrographic lung lesions at 7 days post-challenge. Our data suggest that the recombinant Swinepox Virus encoding HA1 of SIV H1N1 and H3N2 might serve as a promising candidate vaccine for protection against SIV H1N1 and H3N2 infections.
-
immune responses and protective efficacy of a recombinant Swinepox Virus co expressing ha1 genes of h3n2 and h1n1 swine influenza Virus in mice and pigs
Veterinary Microbiology, 2013Co-Authors: Jiarong Xu, Dongyan Huang, Jiaping Xu, Wen Chen, Chengping LuAbstract:The recombinant swine poxVirus rSPV/H3-2A-H1 co-expressing HA1 genes of H3N2 and H1N1 subtype SIV has been constructed and identified. Inoculations of rSPV/H3-2A-H1 yielded ELISA and neutralization antibodies against SIV H1N1 and H3N2, and elicited potent H1N1 and H3N2 SIV-specific INF-γ response from T-lymphocytes in mice and pigs in this study. Complete protection against SIV H1N1 or H3N2 challenge in pigs was observed.
-
immune responses and protection efficacy of a recombinant Swinepox Virus expressing ha1 against swine h3n2 influenza Virus in mice and pigs
Virus Research, 2012Co-Authors: Jiarong Xu, Dongyan Huang, Chengping LuAbstract:Swine influenza Virus (SIV) is not only an important respiratory pathogen in pigs but also a potent threat to human health. Even though immunization with recombinant vaccinia poxViruses expressing protective antigens as a vaccination strategy has been widely used for many infectious diseases, development of recombinant Swinepox Virus (rSPV) vector for this purpose has been less successful. Here, we report the construction of a recombinant Swinepox Virus (rSPV) expressing hemagglutinin (HA1) of H3N2 SIV (rSPV-H3). Immune responses and protection efficacy of the vaccination vector were assessed in both mouse and pig models. Prime and boost inoculations of rSPV-H3 yielded neutralization antibody against SIV and elicited potent H3N2 SIV-specific INF-γ response from T-lymphocytes. Complete protection of pigs against H3N2 SIV challenge was achieved. No pigs showed severe systemic and local reactions and no SIV was found shed from the pigs vaccinated with rSPV-H3 after challenge. The data suggest that the SPV-based recombinant vector expressing HA1 of H3N2 SIV might serve as a promising SIV vaccine for protection against SIV infection.
-
immune responses and protective efficacy of a recombinant Swinepox Virus expressing ha1 against swine h1n1 influenza Virus in mice and pigs
Vaccine, 2012Co-Authors: Jiarong Xu, Dongyan Huang, Chengping LuAbstract:Abstract Swine influenza Virus (SIV) is not only an important respiratory pathogen in pigs but also a potent threat to human health. Although immunization with recombinant poxViruses expressing protective antigens as vaccines has been widely used for against many infectious diseases, development of recombinant Swinepox Virus (rSPV) vector for the purpose has been less successful. Here, we report the construction of a recombinant Swinepox Virus (rSPV-HA1) expressing hemagglutinin (HA1) of H1N1 SIV. Immune responses and protection efficacy of the vaccination vector were evaluated in both the mouse model and the natural host: pig. Prime and boost inoculations of rSPV-HA1 yielded high levels of neutralization antibody against SIV and elicited potent H1N1 SIV-specific IFN-γ response from T-lymphocytes. Complete protection of pigs against H1N1 SIV challenge was observed. No pigs showed evident systemic and local reactions to the vaccine and no SIV shedding was detected from pigs vaccinated with rSPV-HA1 after challenge. Our data demonstrated that the recombinant Swinepox Virus encoding HA1 of SIV H1N1 may serve as a promising SIV vaccine for protection against SIV infection.
-
First insights into the protective effects of a recombinant Swinepox Virus expressing truncated MRP of Streptococcus suis type 2 in mice.
Berliner Und Munchener Tierarztliche Wochenschrift, 2012Co-Authors: Dongyan Huang, Jiarong Xu, Chengping LuAbstract:: To explore the potential of the Swinepox Virus (SPV) as vector for Streptococcus suis vaccines, a vector system was developed for the construction of a recombinant SPV carrying bacterial genes. Using this system, a recombinant Virus expressing truncated muramidase-released protein (MRP) of S. suis type 2 (SS2), designated rSPV-MRP, was produced and identified by PCR, western blotting and immunofluorescence assays. The rSPV-MRP was found to be only slightly attenuated in PK-15 cells, when compared with the wild-type Virus. After immunization intramuscularly with rSPV-MRP, SS2 inactive vaccine (positive control), wild-type SPV (negative control) and PBS (blank control) respectively, all CD1 mice were challenged with a lethal dose or a sublethal dose of SS2 highly virulent strain ZY05719. While SS2 inactive vaccine protected all mice, immunization with rSPV-MRP resulted in 60% survival and protected mice against a lethal dose of the highly virulent SS2 strain, compared with the negative control (P < 0.05). Our data indicate that animals immunized with rSPV-MRP had a significantly reduced bacterial burden in all organs examined, compared to negative controls and blank controls (P
Lei Chen - One of the best experts on this subject based on the ideXlab platform.
-
recombinant Swinepox Virus expressing glycoprotein e2 of classical swine fever Virus confers complete protection in pigs upon viral challenge
Frontiers in Veterinary Science, 2017Co-Authors: Lei ChenAbstract:Classical swine fever (CSF) is a highly contagious and serious viral disease that affects the pig industry worldwide. The glycoprotein E2 of the classical swine fever Virus (CSFV) can induce neutralizing antibodies, and it is widely used for novel vaccine development. To explore the development of a vaccine against CSFV infections, the gene of glycoprotein E2 was inserted into the Swinepox Virus (SPV) genome by homologous recombination. The culture titers of rSPV-E2 remained at about 4.3 ×106 TCID50 for more than 60 passages in PK15 and ST cell lines. The rSPV-E2 could not be replicated in Vero, MDBK or other non-porcine cell lines. After 2-3 passages, the SPV specific gene of rSPV-E2 could not been detected in the non-porcine cell culture. To evaluate the immunogenicity of rSPV-E2, twenty CSFV seronegative minipigs were immunized with rSPV-E2, a commercial C-strain vaccine, wild-type SPV (wtSPV; negative control), or PBS (a no-challenge control). After challenge with CSFV, pigs in the rSPV-E2-immunized group showed significantly shorter fever duration compared with the wtSPV-treated group (P < 0.05). E2-specific antibodies in the rSPV-E2-immunized group increased dramatically after vaccination and increased continuously over time. CSFV genomic copies in the serum of rSPV-E2-immunized pigs were significantly less compared with the wtSPV-treated group at all time points after challenge (P < 0.01). Significant reduction in gross lung lesion scores, histopathological liver, spleen, lung, and kidney lesion scores were noted in the rSPV-E2-immunized group compared with the wtSPV-treated group (P < 0.01). The results suggested that the recombinant rSPV-E2 provided pigs with significant protection from CSFV infections; thus, rSPV-E2 offers proof of principle for the development of a vaccine for the prevention of CSFV infections in pigs.
-
Erratum: Corrigendum: Construction and immunogenicity of a recombinant Swinepox Virus expressing a multi-epitope peptide for porcine reproductive and respiratory syndrome Virus
Scientific Reports, 2017Co-Authors: Zhe Ma, Lei ChenAbstract:Scientific Reports 7: Article number: 43990; published online: 08 March 2017; updated: 21 April 2017 This Article contains errors in the order of Figures 1, 2, 4 and 5 which were inadvertently published as Figures 5, 4, 2 and 1 respectively. The correct Figures appear below. The legends for the Figures are correct.
-
Construction and immunogenicity of a recombinant Swinepox Virus expressing a multi-epitope peptide for porcine reproductive and respiratory syndrome Virus
Scientific Reports, 2017Co-Authors: Huixing Lin, Xin Hou, Zhe Ma, Lei Chen, Hongjie FanAbstract:To characterize neutralizing mimotopes, phages were selected from a 12-mer phage display library using three anti-porcine reproductive and respiratory syndrome Virus (PRRSV) neutralizing monoclonal antibodies: (1) A1; (2) A2; and (3) A7. Of these, A2 and A7 recognize the mimotope, P2, which contains the SRHDHIH motif, which has conserved consensus sequences from amino acid positions 156 to 161 in the N-terminal ectodomain of GP3. The artificial multi-epitope gene, mp2, was designed by combining three repeats of the mimotope P2. The resulting sequence was inserted into the Swinepox Virus (SPV) genome to construct a recombinant Swinepox Virus (rSPV-mp2). The rSPV-mp2 was able to stably express the multi-epitope peptide, mP2, in vitro. The rSPV-mp2 immunized pigs exhibited a significantly shorter fever duration compared with the wtSPV treated group (P
-
construction and immunogenicity of a recombinant Swinepox Virus expressing a multi epitope peptide for porcine reproductive and respiratory syndrome Virus
Scientific Reports, 2017Co-Authors: Lei ChenAbstract:To characterize neutralizing mimotopes, phages were selected from a 12-mer phage display library using three anti-porcine reproductive and respiratory syndrome Virus (PRRSV) neutralizing monoclonal antibodies: (1) A1; (2) A2; and (3) A7. Of these, A2 and A7 recognize the mimotope, P2, which contains the SRHDHIH motif, which has conserved consensus sequences from amino acid positions 156 to 161 in the N-terminal ectodomain of GP3. The artificial multi-epitope gene, mp2, was designed by combining three repeats of the mimotope P2. The resulting sequence was inserted into the Swinepox Virus (SPV) genome to construct a recombinant Swinepox Virus (rSPV-mp2). The rSPV-mp2 was able to stably express the multi-epitope peptide, mP2, in vitro. The rSPV-mp2 immunized pigs exhibited a significantly shorter fever duration compared with the wtSPV treated group (P < 0.05). There was an enhanced humoral and cellular immune response, decreased number of PRRSV genomic copies, and a significant reduction in the gross lung pathology (P < 0.05) was observed following PRRSV infection in rSPV-mp2-immunized animals. The results suggest that the recombinant rSPV-mp2 provided pigs with significant protection against PRRSV infection.
Clarissa R. Damaso - One of the best experts on this subject based on the ideXlab platform.
-
Validation of a real-time PCR assay for detection of Swinepox Virus
Archives of Virology, 2019Co-Authors: Felipe Augusto Souza, Clarissa R. Damaso, Erlânio Marcelo Santos Júnior, Mateus Laguardia-nascimento, Tânia Rosária Pereira Freitas, Anselmo V. Rivetti Júnior, Marcelo Fernandes Camargos, Antônio Augusto Fonseca JúniorAbstract:Swine are the only known hosts of Swinepox Virus (SWPV), the sole member of the genus SuipoxVirus , family Poxviridae . Rapid diagnosis is recommended for appropriate interventions because of the high morbidity associated with this Virus. This study describes a real-time quantitative PCR (qPCR) assay for rapid detection and quantification of SWPV. The detection limit, repeatability, reproducibility, and specificity of this assay were determined. The efficiency was 96%, and the R^2 value was 0.996. The detection limit was 1 fg or 10^−0.5 TCID_50/50 μL. Tests showed that the greatest source of error in the SWPV qPCR assay was variation between analysts rather than different qPCR kits or equipment. All nucleic acids from other Viruses or samples collected from swine were negative in the specificity test. qPCR for SWPV is a new method with tested variables that allows main sources of error in laboratory diagnosis and viral quantification to be identified.
-
One-step duplex polymerase chain reaction for the detection of Swinepox and vaccinia Viruses in skin lesions of swine with poxVirus-related disease.
Journal of Virological Methods, 2015Co-Authors: Maria Luiza G. Medaglia, Natália M.b. Sá, Isadora A. Correa, Luciana J. Costa, Clarissa R. DamasoAbstract:Infection of pigs with Swinepox Virus (SWPV) was reported in Brazil in 2011. SWPV causes a systemic pustular disease in pigs and the symptoms are clinically indistinguishable from those caused by vaccinia Virus (VACV) infection. Pigs infected with VACV have been reported in various countries; however, VACV is endemic in Brazil, India and other countries, where it affects mainly dairy cows, dairy buffaloes and dairy workers causing localized pustules. The transmission of VACV to other susceptible hosts has also been detected in Brazil. Therefore, VACV should be investigated as a possible etiologic agent of pustular skin disorders in pigs. This work describes the development of a one-step duplex assay to detect Swinepox and vaccinia Viruses simultaneously in skin lesions of pigs with generalized pustular disease. The investigation of VACV infection in pigs is important in countries where this zoonosis is endemic and should be differentiated from SWPV infection.
-
Swinepox Virus outbreak, Brazil, 2011.
Emerging Infectious Diseases, 2011Co-Authors: Maria Luiza G. Medaglia, Adriana De Cássia Pereira, Tânia R.p. Freitas, Clarissa R. DamasoAbstract:To the Editor: Swinepox Virus (SWPV), which replicates only in swine, belongs to the SuipoxVirus genus of the Poxviridae family. It is the etiologic agent of a skin disease of pigs, characterized by generalized pustular lesions and associated with high rates of illness (occasionally >80%). It occurs mainly on farms with poor management and housing conditions and affects primarily pigs
-
Swinepox Virus outbreak brazil 2011
Emerging Infectious Diseases, 2011Co-Authors: Maria Luiza G. Medaglia, Adriana De Cássia Pereira, Tânia R.p. Freitas, Clarissa R. DamasoAbstract:To the Editor: Swinepox Virus (SWPV), which replicates only in swine, belongs to the SuipoxVirus genus of the Poxviridae family. It is the etiologic agent of a skin disease of pigs, characterized by generalized pustular lesions and associated with high rates of illness (occasionally >80%). It occurs mainly on farms with poor management and housing conditions and affects primarily pigs <3 months of age; adult pigs show milder signs. The disease is mechanically transmitted by pig lice or through direct animal contact (1). Vaccinia Virus (VACV; OrthopoxVirus genus) also causes a similar pustular disease in pigs that is difficult to distinguish clinically from SWPV infections. VACV infections were common during smallpox vaccination campaigns, when VACV was transmitted to domestic animals from lesions of vaccinees (1,2).
